Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab
This cohort study estimates 5-year standardized risks for any first cancer among patients being treated with biologics for moderate to severe psoriasis.
Authors
- Mads Kirchheiner Rasmussen (ORCID: https://orcid.org/0000-0001-8242-9377)
- Lone Skov (ORCID: https://orcid.org/0000-0002-4784-9680)
- C. Schwarz (ORCID: https://orcid.org/0000-0002-2255-398X)
- Lars Iversen (ORCID: https://orcid.org/0000-0003-1816-4508)
- Trine Bertelsen (ORCID: https://orcid.org/0000-0002-4777-1991)
- Nikolai Loft (ORCID: https://orcid.org/0000-0002-2950-3280)
Institutions
- University of Copenhagen (DK)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1001/jamadermatol.2025.3928
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00